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Background: microRNAs (miRNAs) are a class of small non-coding RNAs that play important roles in carcinogenesis.
In the present study, we investigated the effect of miR-212 on pancreatic ductal adenocarcinoma (PDAC) and its
target protein.
Methods: Quantitative real-time PCR(qRT-PCR) was performed to detect the expression of miR-212 in PDAC tissues
and pancreatic cancer cell lines. miR-212 mimic, miR-212 inhibitor and negative control were transfected into
pancreatic cancer cells and the effect of miR-212 up-regulation and down-regulation on the proliferation, migration
and invasion of cells were investigated. Furthermore, the mRNA and protein levels of Patched-1(PTCH1) were
measured. Meanwhile, luciferase assays were performed to validate PTCH1 as miR-212 target in PDAC.
Results: miR-212 was up-regulated in PDAC tissues and cells.Using both gain-of function and loss-of function
experiments, a pro-oncogenic function of miR-212 was demonstrated in PDAC. Moreover, up-regulated of PTCH1
could attenuate the effect induced by miR-212.
Conclusion: These data suggest that miR-212 could facilitate PDAC progression and metastasis through targeting
PTCH1, implicating a novel mechanism for the progression of PDAC.
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microRNAs (miRNAs) constitute an evolutionarily con-
served class of small, non-coding RNAs whose function
are regulating expression of multiple genes either by
translational suppression or gene degradation via interac-
tions with 3′untranslated regions (UTR) of target mRNAs
[1]. It has been confirmed that miRNAs modulate many
key cellular processes, such as cell growth, cycle, differen-
tiation, and cell death [2,3]. Moreover, Dysregulation of
miRNA expression has been identified in various types of
cancer, and compelling evidence suggest that miRNAs
function as oncogenes or tumor suppressors genes [4,5].
Recently, miRNAs have been discovered to have a role in
progression and metastasis of human cancers [6-11].* Correspondence: akxing8258@gmail.com
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unless otherwise stated.Furthermore, several clinical studies have observed corre-
lations between miRNA expression and recurrence and
survival [12]. The miR-212, which locates at chromosome
17p13.3, was shown to be over-expressed in many cancers,
including non-small cell lung cancer [13], and oral carcin-
oma [14], whereas in other tumors such as hepatocellular
carcinoma [15], gastric cancer [16,17], colorectal cancer
[18], prostate cancer [19], miR-212 was down-expressed.
In the present study, we aimed at exploring the roles
miR-212 played in PDAC and the potential mechanism.
Using gain and loss of function assays, a pro-oncogenic
function of miR-212 in PDAC was observed. Furthermore,
the Hh signal pathway receptor PTCH1 was demonstrated
to be a direct target of miR-212 in PDAC. Our findings
provide an oncogenic role of miR-212 orchestrates in
PDAC and its possible mechanism.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Ethical approval of the study protocol
For the analyzed tissue specimens, all patients were
given informed consent to use excess pathological speci-
mens for research purposes. The protocols employed in
this study and the use of human tissues was approved by
the Ethics Committee of The Sixth People’s Hospital af-
filiated of Shanghai Jiaotong University and conducted
in full accordance with ethical principles, including the
World Medical Association Declaration of Helsinki, and
the local legislation. The manuscript was accompanied
by a statement that the experiments were undertaken
with the understanding and written consent of each sub-
ject and according to the above mentioned principles.
Human tissue specimens and cell lines
Twenty-two PDAC specimens were obtained from The
Sixth People’s Hospital affiliated to Shanghai Jiaotong
University. The matched normal gastric tissue samples
were obtained from tissues that were located 5 cm away
from the tumor margin. The study was approved by the
Ethics Committee of The Sixth People’s Hospital affili-
ated of Shanghai Jiaotong University.
The human pancreatic cancer cells, including PANC-1,
SW1990, BxPC-3 were obtained from the Americacn
Type culture Collection (ATCC, manassas, VA) and the
normal human pancreatic duct epithelial cells were iso-
lated from normal pancreatic tissues as previously de-
scribed [20]. Cells were maintained in DMEM with 10%
FBS (GIBCO, Carlsbad, CA), and were cultured at 37°C
with 5% CO2.
Quantitative real-time PCR(qRT-PCR)
Total RNA was extracted from tissues and cells using
Trizol regent (Invitrogen, Carlsbad, CA), and the re-
verse transcription reactions were performed by random
primers and a Moloney murine leukemia virus reverse
transcriptase kit (Invitrogen) following the manufacturer’s
protocol. Real-time PCR was performed using a standard
SYBR Green PCR kit (Toyobo, Osaka, Japan) protocol on
Applied Biosystems 7500 Real Time PCR system (Applied
Biosystems, Foster City, CA) according to the instruc-
tions. U6 was used as references for miR-212, GAPDH
was used as references for PTCH1. Each sample was ana-
lyzed in triplicate. The 2-ΔΔCt method was used to quantify
the relative levels of gene expression. The primer se-
quences were as follows: RT Primer: CTCAACTGGTG
TCGTGGAGTCGGCAATTCAGTTGAGGGCCGTGA,
has-miR-212 forward: ACACTCCAGCTGGGTAACA
GTCTCCAGTC; U6 SLRT: CTCAACTGGTGTCGTG
GAGTCGGCAATTCAGTTGAGAAAATATG, U6 for-
ward: ACACTCCAGCTGGGCGCAAATTCGTGAAGC.
PTCH1 forward: GCTTCCCGTGCTTTTGTCTT, re-
verse: CTGCAGCTCAATGACTT.Transient transfection
miR-212 mimic, miR-212 inhibitor, negative control were
obtained from GenePharma (Shanghai, China) and the se-
quences were as follows: miR-212 mimic: sense (5′ to 3′)
UAACAGUCUCCAGUCACGGCC, antisense (5′ to 3′)
CCGUGACUGGAGACUGUUAUU. miR-212 Inhibi-
tor: sense (5′ to 3′) GGCCGUGACUGGAGACUGUUA.
Negative control: sense (5′ to 3′)UUCUCCGAACGUGU
CACGUTT, antisense (5′ to 3′)ACGUGACACGUUCG
GAGAATT. Cells were seeded in 6-well plates at a con-
centration of 1 × 105 and cultured in medium without
antibiotics for approximately 24 h before transfection.
Cells were transiently transfected with miR-212 mimic,
miR-212 inhibitor or negative control(NC), at a final
concentration of 200nM. After 6 h incubation at 37°C
and 5% CO2, the medium was re-placed with fresh
culture medium.
Cell proliferation assay
Cell proliferation analysis was performed with Cell
Counting Kit-8 (Dojindo, Kumamoto, Japan) according
to the manual of the manufacturer. Briefly, PDAC cells
were plated in 96-well plates in triplicate at 1 × 104 cells
each well and cultured in the growth medium. Cells
were examined at 24, 48, 72, and 96 h. CCK-8 (10 μl)
was added to each well at different time points. After an
incubation of 1 h at 37°C, absorbance was measured at
450 nm. Five independent experiments were performed.
Colony formation assay
2000 of each transfected cells were plated in six-well
plate and cultured for 14 days. Then cells were fixed and
stained with methanol for 30 min, followed by 0.5% crys-
tal violet for 20 min. Visible colonies were quantified in
four different fields and the mean value was calculated.
Cell migration and invasion assays
The wound healing assay was used to examine cell mi-
gration. The migration status was determined by meas-
uring the movement of cells into a scraped area created
by a 200 μl pipette tip. After wound scratching, cells
were cultured in media supplemented with 0.1% FBS to
eliminate the effect of cell proliferation. The process of
wound closure was photographed at 24 h. Cell invasion
was examined using a extracellular matrix membrane
(BD Biosciences, San Jose, CA). Cells were suspended in
serum-free medium and placed in the top chambers,
and complete medium containing 10% FBS was added to
the bottom chambers. The chambers were then incu-
bated for 12 h at 37°C with 5% CO2. After incubation,
the noninvasive cells were gently removed from the top
wells with a cotton-tipped swab and the chambers were
fixed with methanol for 30 min. The chambers were
then stained with crystal violet for another 30 min. Four
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inverted microscope (Olympus, Japan), and each experi-
ment was repeated three times.
Luciferase activity assay
PANC-1 cells were co-transfected with miR-212 mimic
or negative control (NC) and wild type (WT) or the
mutated 3′UTR (Mut) of PTCH1. 48 h later, cells were
collected and luciferase activity was assayed using
dual-luciferase assay system (Promega, Wiscosin, WI).
Western blot analysis
Cells were washed with PBS and lysed for 10 min on ice in
RIPA buffer (Thermo Scientific, Waltham, MA). Protein
concentration was measured using the BCA assay (Thermo
Scientific, Waltham, MA). The protein fractions were re-
suspended in loading buffer and denatured at 100°C for
10 min. Total proteins (20 μg/lane) were separated on
10% SDS polyacrylamide gels and transferred to PVDF
membranes. The membranes were then blocked in 5% fat-
free milk in TBST buffer (0.1% Tween-20) for 2 h at room
temperature. The rabbit anti-human polyclonal antibody
was used in conjunction with 0.4 μg/ml of anti-species
conjugated horseradish peroxidase (Upstate, Lake Placid,
NY), and bands were detected by chemiluminescence
(Amersham Pharmacia Inc, Piscataway, NJ).
Immunohistochemistry
PTCH1 was detected in paraffin-embedded tumor tissues
and adjacent normal tissues. Immunohistochemistry stain-
ing was performed according to the manufacturer instruc-
tions. each slide was deparaffinized in 60°C, followed by
treatment with xylene and graded alcohol. After the anti-
gen retrieval and being blocked with 5% bovine serum al-
bumin, tissue slides were immunohistochemically stained
by antibody against PTCH1 (Santa Cruz Biotech, Santa
Cruz, CA), then visualized by standard avidin–biotinylated
peroxidase complex method. Hematoxylin was used for
counterstaining and morphologic images were observed
with Olympus BX51 microscope.
Statistical analysis
All data are expressed as mean ± standard error of mean
(SEM), Values of P < 0.05 were considered statistically
significant. Statistical analyses were analyzed using Stu-
dent’s t-test. All analyses were performed with SPSS
19.0.
Results
Upregulated miR-212 expression in PDAC tissues and cell
lines
We firstly tested the expression of miR-212 in PDAC tissues
by qRT-PCR from 22 patients who underwent pancreatico-
duodenectomy. The results verified that the expression ofmiR-212 was higher in PDAC tissues compared with adja-
cent normal tissues (Figure 1A). We then examined the
expression level of miR-212 in PDAC cell lines (PANC-1,
SW1990, BxPC-3). Compared to normal human pancre-
atic duct epithelial cells, miR-212 expression was signifi-
cantly upregulated in cancer cell lines (Figure 1B).
miR-212 increased PDAC cell growth and motility in vitro
PANC-1 cells were transfected with miR-212 mimic or
miR-212 inhibitor or NC. To explore whether miR-212 have
an effect on PDAC cell proliferation, CCK-8 assays were
measured. The viability of the miR-212 mimic group was
higher compared with NC group, whereas, the miR-212 in-
hibitor group was lower than NC group (Figure 2A). Simi-
larly, Forced expression of miR-212 significantly increased
colony formation of PANC-1 cells (Figure 2B).
To test the metastatic ability of miR-212, the wound
healing assays were performed in vitro, and it turned out
that miR-212 significantly enhanced PANC-1 cell migra-
tion capabilities (Figure 2C,D). Similar results were ob-
served in cell invasion assays (Figure 2E,F).
PTCH1 was a target of miR-212 in PDAC cells
Targetscan software (http://www.targetscan.org/) showed
that the 3′UTR of human PTCH1 contains putative target
sites for miR-212 (Figure 3A). To confirm the target sites,
the 3′UTR and mutated 3′UTR of human PTCH1 were
amplified and inserted into pGL3b vector. Luciferase ac-
tivity assay found that miR-212 mimic significantly sup-
pressed the WT but not the Mut 3′UTR luciferase activity
in PANC-1 cells (Figure 3B). Furthermore, overexpression
of miR-212 significantly inhibited PTCH1 mRNA and
protein levels in PANC-1 cell, while inhibition of miR-212
showed opposite effects (Figure 3C,D).
PTCH1 was negatively correlated with miR-212 in PDAC
tissues
Next, we detected PTCH1 in PDAC tissues and corre-
sponding non-tumor tissues. Immunostaining showed
that 18 of 22(81%) adjacent normal tissues were positive
for PTCH1 (Figure 4A,b). In contrast, 16 of 22(72%)
PDAC tissues showed less immunostaining (Figure 4A,a).
We also found that PTCH1 mRNA was significantly de-
creased in PDAC tissues compared with corresponding
normal tissues (Figure 4B). Moreover, PTCH1 mRNA
level was inversely correlated with miR-212 level in PDAC
tissues (Figure 4C).
Overexpression of PTCH1 attenuated miR-212 induced
PDAC cell proliferation, migration, and invasion
To investigate whether overexpression could reverse
miR-212 induced cell proliferation, migration, and inva-
sion. PANC-1 cells were co-transfected with miR-212 mimic
and PTCH1 or miR-212 mimic or NC. Cell proliferation
Figure 1 miR-212 was up-regulated in pancreatic ductal adenocarcinoma (PDAC) tissues and cell lines. (A) The expression levels of miR-212
were examined by qRT-PCR in PDAC tissues and paired adjacent normal tissues of twenty-two patients. Transcript levels were normalized to U6
expression. (B) qRT-PCR analysis of relative miR-212 expression in five PDAC cell lines and normal pancreatic ductal epithelial cells. Transcript levels
were normalized to U6 expression. Date are shown as mean ± SEM of three independent experiments. *P < 0.05.
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invasion assays (Figure 5D,E) showed that overexpres-
sion of PTCH1 significantly attenuated miR-212 in-
duced PDAC cell proliferation, migration, and invasion.
Discussion
Accumulating evidences have revealed that miRNAs par-
ticipate in the progression of many types of cancer by
targeting multiple genes which involved in the progres-
sion and metastasis [21]. Thereby, identification of spe-
cific miRNAs may provide clues for the diagnosis and
therapy of patients with cancer. Here, we found that theFigure 2 miR-212 promoted PDAC cell proliferation and motility. (A) CC
of miR-212 mimic significantly increased PANC-1 cells proliferation, whi
cells proliferation. (B) Colony formation assay showed that miR-212 mimic in
inhibited cell colony formation. (C) The wound healing assays showed the mig
inhibitor, statistical analysis is shown in (D). (E) Transwell assays showed that m
inhibitor weaken cell invasion. statistical analysis is shown in (F). Three indepeexpression of miR-212 was significantly up-regulated in
PDAC tissues and cells lines, consistent with the study of
Park [22]. Next, in vitro experiments were performed to
test the pro-oncogenic roles of miR-212 played in PDAC.
As we expected, a pro-proliferative, pro-migratory, pro-
invasive effect of miR-212 was observed in PDAC cells,
while miR-212 inhibitor suppressed this effect. Further-
more, we showed that PTCH1 was a direct target of miR-
212 in PDAC cells, consistent with Li study, PTCH1 was a
direct target of miR-212 in non-small lung cancer [13].
PTCH1 is a member of the hedgehog (Hh) signaling
pathway [23]. The Hh signaling pathway is crucial in theK-8 assays performed to examine PANC-1 cells proliferation. Transfection
le transfection of miR-212 inhibitor significantly decreased PANC-1
creased PANC-1 cells colony formation, while miR-212 inhibitor significantly
ration ability of PANC-1 cells transfected with miR-212 mimic or miR-212
iR-212 significantly enhanced PANC-1 cell invasion, while miR-212
ndent experiments were performed. *P < 0.05.
Figure 3 PTCH1 was a direct target of miR-212 in PDAC cells. (A) The miR-212 biding site predicted in the 3′UTR of PTCH1 mRNA. Mutant
was generated at the seed region of PTCH1 3′UTR as indicated by the underline. A 3′UTR fragment of PTCH1 mRNA containing wild-type (WT) or
mutant (Mut) of the miR-212 binding sequence was cloned into the downstream of the luciferase gene in pGL3b vector. (B) PANC-1 cells were
transfected with pGL3b reporter vectors containing either wild-type (WT) or mutant (Mut) PTCH1 3′UTR with either miR-212 mimic or miR-212
inhibitor, or negative control (NC). Luciferase activity was determined 48 h after transfection. (C) PTCH1 mRNA was detected by qRT-PCR in
PANC-1 cells transfected with miR-212 mimic or NC or miR-212 inhibitor. (D) The protein levels of PTHC1 were examined by western blot assays
transfected with miR-212 mimic or miR-212 inhibitor or NC. *P < 0.05.
Figure 4 PTCH1 was negatively correlated with miR-212 in PDAC tissues. (A) Immunostaining of PTCH1 in PDAC tissues. a. Immunostaining
of PTCH1was very weekly positive in PDAC tissues. b. PTCH1was positive in adjacent normal tissues. (B) PTCH1 mRNA level was examined by
qRT-PCR and it was remarkably decreased in PDAC tissues. (C) PTCH1 mRNA level was inversely correlated with miR-212 level in PDAC tissues.
(Spearman’s correlation analysis,r = −0.5157, P = 0.001). *P < 0.05.
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Figure 5 PTCH1 contributes to miR-212 induced proliferation, migration, invasion of PDAC cells. (A) PANC-1 cells were co-transfected with
miR-212 mimic and PTCH1 or miR-212 mimic or NC, CCK-8 assay was used to examine proliferation. (B) The wound healing assay was used to
assay migration of PANC-1 cells transfected with miR-212 mimic and PTCH1 or miR-212 mimic, statistical analysis is shown in (C). (D) The invasion
assay showed invasion capability of PANC-1 cells tranfected with miR-212 mimic and PTCH1 or miR-212 mimic, statistical analysis is shown in
(E). *P < 0.05.
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while abnormal activation of Hh signaling pathway is
highly involved in tumor progression and metastasis
[24,25]. As a tumor suppressor gene, PTCH1 inhibits
tumor cell growth and motility by blocking the Hh sig-
naling pathway [26]. PTCH1 is down-regulated in some
malignant cancers, such as liver, breast, and esophageal
cancer [27-29]. The ectopic expression of PTCH1 may
leads to the loss of its normal inhibitory function on
Smo, another member of Hh signaling pathway, result-
ing in the abnormal activation of the Hh signaling path-
way, as well as the downstream transcription factor Gli1.
The abnormal activation of Hh signaling pathway can
lead to the promotion of tumor cell proliferation, migra-
tion, and invasion [30-32]. In this study, we showed that
the expression level of miR-212 was inversely correlated
with PTCH1 in PDAC tissues, and up-regulated PTCH1
could attenuate the pro-oncogenic effect induced by
miR-212 in PDAC cells. These results indicated that the
overexpression of miR-212 mediated PDAC cell growth,
migration, and invasion may partially through inhibiting
PTCH1 expression.
Conclusions
Taken together, this study showed that miR-212 was up-
regulated in PDAC samples and cell lines, and both
gain-of and loss of-function demonstrated that miR-212
enhanced cell proliferation, colony formation, migration,and invasion of PDAC cells. PTCH1 was identified as a
target of miR-212, and up-regulated PTCH1 partially at-
tenuated the pro-oncogenic effect or miR-212, indicating
that miR-212 may act as an oncogene and miR-212/
PTCH1 present a potential target for PDAC therapy.
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